Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review.

ABSTRACT:

Importance

The introduction of human epidermal growth factor receptor 2 (HER2) directed therapy has transformed the outcomes of patients with advanced breast cancer (BC). However, HER2 positive breast cancer has a predilection for the central nervous system (CNS) which is associated with significant morbidity and mortality. Understanding the intracranial activity of novel HER2 directed agents is key to developing treatments as well as possible preventative strategies for HER2-positive CNS disease.

Observations

Using protocols and data from published phase III clinical trials for locally advanced/metastatic HER2-positive breast cancer since the licensing of single agent trastuzumab for advanced BC we review the central nervous system related aspects. This includes CNS related

SUBMITTER: Bhogal T 

PROVIDER: S-EPMC8961215 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature